| Variable |
|
Number |
% |
| Age |
Median (range) |
61 (29-73) |
|
| Sex |
Male |
18 |
69 |
| |
Female |
8 |
31 |
| Histology |
Follicular |
14 |
53 |
| |
Transformed follicular |
2 |
8 |
| |
NLPHLa |
3 |
12 |
| |
Marginal zone lymphoma |
2 |
8 |
| |
Mantle cell lymphoma |
2 |
8 |
| |
DLBCLb |
2 |
8 |
| |
Small lymphocytic |
1 |
3 |
| Disease Stage at study entry |
I/II |
10 |
38 |
| |
III/IV |
16 |
62 |
| Disease Status at study entry |
Partial remission |
2 |
8 |
| |
Progressive disease |
24 |
92 |
| Follicular lymphoma (n=14) |
FLIPIc low (0-1) |
9 |
64 |
| |
FLIPI intermediate (2) |
2 |
14 |
| |
FLIPI high (>2) |
3 |
22 |
| Prior therapies |
Median (range) |
2 (1-7) |
|
| |
1-2 |
16 |
62 |
| |
>2 |
10 |
38 |
| Prior rituximab therapy |
|
24 |
92 |
| Prior ASCTd |
|
7 |
27 |
| Bone marrow infiltration |
|
4 |
15 |
aNLPHL: Nodular Lymphocyte Predominant Hodgkin’s Lymphoma
bDLBCL: Diffuse Large B Cell Lymphoma
cFLIPI: Follicular Lymphoma International Prognostic Index
dASCT: Autologous Stem Cell Transplant |
